RWE of 1st Line Treatment With ATO/ATRA for Adult APL

This real-world evidence study collects data from adults with acute promyelocytic leukemia (APL — a specific type of blood cancer) who are being treated with the current standard combination of ATO (arsenic trioxide) and ATRA (all-trans retinoic acid). The study tracks how well this treatment works in everyday clinical settings outside of formal trials. **You may be eligible if...** - You are 18 or older - You have a new confirmed diagnosis of APL (acute promyelocytic leukemia) with the characteristic gene alteration (PML-RARα fusion) - You have not received any prior treatment for APL - You have given written informed consent **You may NOT be eligible if...** - You have another active cancer requiring treatment at the same time - You have already received treatment for APL - You have certain heart rhythm problems (long QT syndrome, QTc above 450ms, significant arrhythmias, or a specific type of heart conduction block) - You have very severe heart failure (Stage III–IV) - You have severely impaired kidney or liver function (unless caused by the leukemia itself) - You have severe psychiatric illness - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.